'Alien: Resurrection' is the fourth installment in the iconic franchise, though later on more would follow, as well as spinoffs involving Predators Medicare update: New ID verification coming for ...

Charlie Hunnam plays Jax, the Vice President (and later President) of the eponymous chopper club and son of a founding member ...

Why Dope Thief — starring Brian Tyree Henry and Wagner Moura — was one of TV Scholar's favorite watches this year. (Photo illustration: Yahoo News; photo: Apple TV) ...

Pluribus’ latest episode shed light on where the Alien RNA came from. Additionally, the episode also revealed how The Others communicate and their intentions with everything that they’ve learnt on ...

Why you should watch it: The Pitt single-handedly reinvigorated the medical genre with its fresh approach, and in the process, became one of the biggest shows of 2025. The premise of the show is ...

Sigourney Weaver revealed how her late actress mother, Elizabeth Inglis, tried to discourage her from following in her footsteps. Inglis was a British actress who had a successful stage career in the ...

Every TV season is made up of a certain number of episodes, and each TV episode is made up of a certain number of scenes. The best of those scenes linger in the memory long after you’ve moved on to ...

James Cameron might be an iconic director now, but in the early '80s, he was a little-known creator just starting. His first film, 1982's Piranha II: The Spawning, wasn't great, to put it mildly.

It's been safe to say for a while now that CBS and Showrunner Elwood Reid's Justin Hartley-starring Tracker is a pretty huge hit for the network. But sometimes, you need end-of-the-year lists to ...

Why can’t we just leave well enough alone? Oh yeah, Hollywood capitalism. If a movie makes money, we’re going to get another installment of the IP. Maybe not within a year or two, but at some point.

As the FDA steadily churns out a stream of untitled letters chastising pharmaceutical advertisers’ direct-to-consumer materials, a commercial for Bristol Myers Squibb’s Cobenfy is taking its turn in ...